Loading company…
VaxCell Biotherapeutics develops patient-specific cancer immunotherapies using immune cell platforms.
Established in 2010 and based in South Korea, VaxCell Biotherapeutics develops patient-specific cancer immunotherapies. Its platforms include Vax-NK, Vax-DC, Vax-CARs, and Vaxleukin-15. The company has developed immune cell therapies using natural killer and dendritic cells and is conducting phase 2 clinical trials. It was listed on KOSDAQ in 2020.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in